Company Profile
Olema Pharmaceuticals, Inc. Stock Price, News & Analysis
Company overview
Business overview
Olema Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Olema Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Olema Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Olema Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
OLMA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Olema’s catalysts are palazestrant and the broader oral SERD strategy, with breast-cancer combination data the main thing to watch. The market will care about whether the asset can keep looking differentiated.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Olema Oncology to Participate in Upcoming Investor Conferences
Source: Olema Pharmaceuticals, Inc.
- 02
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Source: Olema Pharmaceuticals, Inc.
- 03
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Source: Olema Pharmaceuticals, Inc.
- 04
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Source: Olema Pharmaceuticals, Inc.
- 05
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Olema Pharmaceuticals, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.